Core Insights - Progyny, Inc. is actively participating in several investor conferences in March 2026, showcasing its leadership in women's health and family building solutions [1][2][3] Group 1: Upcoming Conferences - Mark Livingston, Chief Financial Officer, will engage in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, at 10:40 a.m. Eastern Time [2] - Pete Anevski, Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 11, 2026, at 1:00 p.m. Eastern Time [2] - Melissa Cummings, Chief Operating Officer, will join a panel discussion on fertility technology and women's health at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, at 12:00 p.m. Eastern Time, followed by another fireside chat with Pete Anevski at 3:00 p.m. Eastern Time [3] Group 2: Company Overview - Progyny is recognized as a global leader in women's health and family building solutions, trusted by leading employers, health plans, and benefit purchasers [4] - The company aims to provide comprehensive, inclusive, and intentionally designed solutions that benefit employers, patients, and physicians [4] - Progyny's benefits solution includes concierge support, coaching, education, and digital tools, along with access to a premier network of fertility and women's health specialists [5] Group 3: Recognition and Awards - Progyny has received multiple accolades, including being named a TIME100 Most Influential Company, CNBC Disruptor 50, and recognized by Modern Healthcare, Forbes, Financial Times, INC. 5000, and Crain's Fast 50 for NYC [6]

Core Insights - Progyny, Inc. reported a record revenue of $318.4 million for Q4 2025, reflecting a 6.7% increase year-over-year, and a full-year revenue of $1.288 billion, a 10% increase compared to the previous year [1][3][9] - The company generated a record operating cash flow of $210.2 million for the full year and returned approximately $160 million to shareholders through share repurchases [1][2][13] - Progyny issued financial guidance for 2026, indicating expectations for continued revenue growth for the tenth consecutive year [1][24] Financial Performance - **Fourth Quarter Highlights**: - Revenue: $318.4 million, up 6.7% from $298.4 million in Q4 2024 [3][5] - Gross Profit: $76.9 million, a 21% increase from $63.4 million in Q4 2024 [3][6] - Net Income: $12.5 million, or $0.14 per diluted share, compared to $10.5 million, or $0.12 per diluted share in Q4 2024 [3][7] - Adjusted EBITDA: $51.4 million, an 8.2% increase from $47.5 million in Q4 2024 [3][8] - **Full Year Highlights**: - Revenue: $1.288 billion, a 10% increase from $1.167 billion in 2024 [3][9] - Gross Profit: $304.5 million, a 20% increase from $253.4 million in 2024 [3][10] - Net Income: $58.5 million, or $0.65 per diluted share, compared to $54.3 million, or $0.57 per diluted share in 2024 [3][11] - Adjusted EBITDA: $222.1 million, a 12% increase from $198.8 million in 2024 [3][12] Cash Flow and Shareholder Returns - The company reported net cash provided by operating activities of $210.2 million for 2025, compared to $179.1 million in 2024 [13] - Share repurchase activity included the purchase of approximately 6.5 million shares, returning about $160 million to shareholders [1][15] Client and Market Expansion - As of December 31, 2025, Progyny had 555 fertility and family building clients, up from 473 clients a year earlier [16] - The company anticipates having approximately 600 clients in 2026, representing an estimated 7.2 million covered lives [22] Financial Guidance - For 2026, revenue is projected to be between $1.355 billion and $1.405 billion, reflecting growth of 5.1% to 9.0% [24] - Net income is expected to be between $95.4 million and $106.1 million, or $1.10 to $1.22 per diluted share [24]

Core Insights - Progyny, Inc. will report its financial results for the fourth quarter and full year ended December 31, 2025, on February 26, 2026, after market close [1] - A conference call will be held at 4:45 p.m. Eastern Time to discuss the results, with a press release issued prior to the call [1] - The company is recognized as a leader in women's health and family building solutions, serving major employers and health plans [4] Financial Reporting - The financial results will cover the quarterly period and full year ending December 31, 2025 [1] - Participants can access the conference call via specific dial-in numbers for U.S. and international callers [2] - An audio replay of the call will be available until March 5, 2026 [2] Company Overview - Progyny is headquartered in New York City and has received multiple accolades for its growth and influence in the healthcare sector [6] - The company offers a benefits solution that includes concierge support, coaching, education, and access to a network of fertility and women's health specialists [5] - Progyny aims to provide comprehensive and inclusive solutions that benefit employers, patients, and physicians [4]

Core Insights - Progyny, Inc. will report its financial results for the quarter ending September 30, 2025, on November 6, 2025, after market close [1] - A conference call will be held at 4:45 PM Eastern Time to discuss the financial results [1] - The company is recognized as a leader in women's health and family building solutions, serving major employers and health plans [4][6] Financial Reporting - Financial results will be announced via a press release prior to the conference call [1] - Participants can access the conference call through specific dialing instructions provided for both U.S. and international participants [2] Company Overview - Progyny is a global leader in women's health and family building solutions, aiming to help individuals achieve their family and health goals [4] - The company offers a benefits solution that includes concierge support, coaching, education, and access to a network of fertility and women's health specialists [5] - Progyny has received multiple accolades for its growth and influence in the healthcare sector, including recognition from TIME, CNBC, and Forbes [6]

Core Insights - Progyny, Inc. has appointed Elizabeth Bierbower to its Board of Directors, enhancing its leadership team with her extensive healthcare experience [1][2] - Bierbower has over 30 years of experience in the healthcare industry, having held significant roles in major health plans and provider services [2][3] - The company aims to expand its women's health and family building solutions, focusing on delivering value to members, clients, and shareholders [2][4] Company Overview - Progyny is recognized as a global leader in women's health and family building solutions, serving leading employers and health plans [5][7] - The company provides comprehensive benefits solutions that include concierge support, education, and access to a network of specialists, driving optimal clinical outcomes and reducing healthcare costs [6][5] - Progyny has received multiple accolades for its growth and influence, including being named a TIME100 Most Influential Company and a CNBC Disruptor 50 [7] Leadership and Strategy - Elizabeth Bierbower's leadership experience includes roles at Friday Health Plans and Humana, where she held various senior positions [2][3] - Her appointment is expected to support Progyny's strategy to innovate and expand its product offerings in women's health [2][4] - Bierbower expressed enthusiasm about joining Progyny at a pivotal time for the company's growth and commitment to high-quality care [4]

Core Insights - Progyny has appointed Melissa Cummings as the first Chief Operating Officer (COO) and Geoffrey Clapp as the first Chief Product Officer (CPO) to enhance operational excellence and innovation in women's health and family building [1][2] - The company serves over 530 leading employers, covering 6.7 million contracted lives, and continues to evolve its offerings, including the new Parent and Child Well-being program and doula support [4] Leadership Appointments - Melissa Cummings brings 30 years of healthcare experience, previously serving as Executive Vice President and Chief Customer Officer at Blue Cross & Blue Shield of Rhode Island [2][3] - Geoffrey Clapp has over two decades of experience in healthcare technology and product development, previously leading strategy at Optum Health Solutions [3][4] Company Vision and Strategy - Progyny aims to set a new standard in healthcare with its unique model and commitment to high-touch care, addressing care gaps in women's health [3] - The leadership team is focused on scaling Progyny's mission and impact, anticipating future member needs while delivering immediate value [4] Market Position - Progyny is recognized as a leader in women's health and family building solutions, trusted by major employers and health plans [6][7] - The company has received multiple accolades, including being named a TIME100 Most Influential Company and a CNBC Disruptor 50 [7][8]